SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $156

Barclays maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $143 to $156.

Benzinga · 05/07/2020 14:43

Barclays maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $143 to $156.